PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
35087525-9	2021	VX-745, the p38 MAP kinase inhibitor significantly decreased IL-1beta- and LPS-induced pleckstrin levels at both the mRNA and the protein level.	VX-745	0-6	mitogen-activated protein kinase 14	Homo sapiens	12-26
35087525-9	2021	VX-745, the p38 MAP kinase inhibitor significantly decreased IL-1beta- and LPS-induced pleckstrin levels at both the mRNA and the protein level.	VX-745	0-6	interleukin 1 alpha	Homo sapiens	61-69
35087525-9	2021	VX-745, the p38 MAP kinase inhibitor significantly decreased IL-1beta- and LPS-induced pleckstrin levels at both the mRNA and the protein level.	VX-745	0-6	pleckstrin	Homo sapiens	87-97
34044875-0	2021	A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer"s disease.	VX-745	109-121	mitogen-activated protein kinase 14	Homo sapiens	82-91
34044875-10	2021	Significantly reduced CSF levels with neflamapimod treatment, relative to placebo, were evident for T-tau [difference (95% CI): -18.8 (-35.8, -1.8); P=0.031] and p-tau181 [-2.0 (-3.6, -0.5); P=0.012], with a trend for neurogranin [-21.0 (-43.6, 1.6); P=0.068].	VX-745	38-50	neurogranin	Homo sapiens	218-229
29687023-2	2018	Methods: Sixteen patients with early AD received a highly selective p38alpha inhibitor (neflamapimod) for 84 days (12 weeks).	VX-745	88-100	mitogen-activated protein kinase 14	Homo sapiens	68-76
32326654-1	2020	To test the hypothesis that p38alpha-MAPK plays a critical role in the regulation of E3 ligase expression and skeletal muscle atrophy during unloading, we used VX-745, a selective p38alpha inhibitor.	VX-745	160-166	mitogen activated protein kinase 14	Rattus norvegicus	28-36
32326654-1	2020	To test the hypothesis that p38alpha-MAPK plays a critical role in the regulation of E3 ligase expression and skeletal muscle atrophy during unloading, we used VX-745, a selective p38alpha inhibitor.	VX-745	160-166	mitogen activated protein kinase 14	Rattus norvegicus	180-188
30526042-5	2019	In this study, we show that a p38 inhibitor (VX-745) up-regulates the expression of Pax6 during osteoclast differentiation.	VX-745	45-51	mitogen-activated protein kinase 14	Homo sapiens	30-33
30526042-5	2019	In this study, we show that a p38 inhibitor (VX-745) up-regulates the expression of Pax6 during osteoclast differentiation.	VX-745	45-51	paired box 6	Homo sapiens	84-88
33275615-4	2020	Accordingly, an oral, brain-penetrant, small molecule p38alpha inhibitor, neflamapimod, was evaluated as a subacute phase stroke treatment to promote functional recovery.	VX-745	74-86	mitogen activated protein kinase 14	Rattus norvegicus	54-62
33275615-5	2020	Neflamapimod administration to rats after transient middle cerebral artery occlusion at two dose levels was initiated outside of the previously characterized therapeutic window for neuroprotection of less than 24 hours for p38alpha inhibitors.	VX-745	0-12	mitogen activated protein kinase 14	Rattus norvegicus	223-231
29181493-0	2017	Neflamapimod: Clinical Phase 2b-Ready Oral Small Molecule Inhibitor of p38alpha to Reverse Synaptic Dysfunction in Early Alzheimer"s Disease.	VX-745	0-12	mitogen-activated protein kinase 14	Homo sapiens	71-79
29316898-5	2018	Here, we test if timed application of the specific p38 MAPK inhibitor VX-745 reduces glioma cell invasive properties in vitro.	VX-745	70-76	mitogen-activated protein kinase 14	Mus musculus	51-59
29316898-13	2018	Inhibition of p38 MAPK activity with VX-745 led to cell-type-specific period changes in the molecular clock.	VX-745	37-43	mitogen-activated protein kinase 14	Mus musculus	14-17
25836052-3	2015	For the first time, VX-745, a highly selective p38 MAPK inhibitor, demonstrated in vivo bioactivity, similar to dexamethasone activity, following intra-articular administration in an antigen-induced arthritic (AIA) mouse model.	VX-745	20-26	mitogen-activated protein kinase 14	Mus musculus	47-55
25836052-4	2015	The in vitro bioactivity of VX-745 was also shown on synoviocytes, reducing the IL-6 concentration.	VX-745	28-34	interleukin 6	Homo sapiens	80-84
24900264-3	2011	Advancing the SAR of this series led to the eventual discovery of 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenylthio)-6H-pyrimido[1,6-b]pyridazin-6-one (VX-745).	VX-745	66-149	sarcosine dehydrogenase	Homo sapiens	14-17
21426137-0	2010	Gram-scale synthesis of the p38alpha MAPK-inhibitor VX-745 for preclinical studies into Werner syndrome.	VX-745	52-58	mitogen-activated protein kinase 14	Homo sapiens	28-36
21426137-1	2010	BACKGROUND: The ATP-competitive p38alpha MAPK inhibitor VX-745 exhibits an exquisite kinase selectivity profile, is effective in blocking p38 stress signaling in Werner syndrome dermal fibroblasts, has efficacy in clinical trials and may have therapeutic value against Werner syndrome.	VX-745	56-62	mitogen-activated protein kinase 14	Homo sapiens	32-40
21426137-1	2010	BACKGROUND: The ATP-competitive p38alpha MAPK inhibitor VX-745 exhibits an exquisite kinase selectivity profile, is effective in blocking p38 stress signaling in Werner syndrome dermal fibroblasts, has efficacy in clinical trials and may have therapeutic value against Werner syndrome.	VX-745	56-62	mitogen-activated protein kinase 14	Homo sapiens	32-35
21426137-5	2010	CONCLUSION: This method delivers the p38 inhibitor VX-745 in sufficient quantities for preclinical studies to rescue the aging phenotype in Werner syndrome.	VX-745	51-57	mitogen-activated protein kinase 14	Homo sapiens	37-40
19055838-6	2008	RESULTS: SB-203580 and VX-745 are both potent inhibitors of p38 with IC50s of 136 +/- 64 nM and 35 +/- 14 nM (mean +/- S.D.	VX-745	23-29	mitogen-activated protein kinase 14	Homo sapiens	60-63
19778055-4	2009	The inhibitory activity of VX-745 against p38alpha MAPK is confirmed in Werner syndrome dermal fibroblasts at 1.0 microM concentration by immunoblot assay.	VX-745	27-33	mitogen-activated protein kinase 14	Homo sapiens	42-50
19055838-18	2008	CONCLUSION: SB203580 and VX-745 demonstrated attenuation of both cartilage degeneration and pain in animal models and suggest that p38 inhibitors may be a useful approach for the treatment of osteoarthritis.	VX-745	25-31	mitogen-activated protein kinase 14	Homo sapiens	131-134
12482439-2	2003	These analogues are hybrids of a pyridinylimidazole p38alpha inhibitor reported by Merck Research Laboratories and VX-745.	VX-745	115-121	mitogen activated protein kinase 14	Rattus norvegicus	52-60
17659871-1	2007	The p38 mitogen-activated protein kinase inhibitor VX-745 is prepared rapidly and efficiently in a four-step sequence using a combination of conductive heating and microwave-mediated steps.	VX-745	51-57	mitogen-activated protein kinase 14	Homo sapiens	4-7
11892915-6	2001	The targeting of p38 MAPK by VX-745 was associated with the suppression of the release of inflammatory mediators, including interleukin (IL)-1beta and tumor necrosis factor (TNF)alpha, known to be implicated in exacerbating the pathophysiology of RA [273648], [368149], [371548], [372054], [408713].	VX-745	29-35	interleukin 1 beta	Homo sapiens	124-146
12393542-2	2003	In this study, we demonstrate that the specific p38 MAPK inhibitor VX-745 inhibits interleukin 6 (IL-6) and vascular endothelial growth factor (VEGF) secretion in bone marrow stromal cells (BMSCs), without affecting their viability.	VX-745	67-73	mitogen-activated protein kinase 14	Homo sapiens	48-51
12393542-2	2003	In this study, we demonstrate that the specific p38 MAPK inhibitor VX-745 inhibits interleukin 6 (IL-6) and vascular endothelial growth factor (VEGF) secretion in bone marrow stromal cells (BMSCs), without affecting their viability.	VX-745	67-73	interleukin 6	Homo sapiens	83-96
12393542-2	2003	In this study, we demonstrate that the specific p38 MAPK inhibitor VX-745 inhibits interleukin 6 (IL-6) and vascular endothelial growth factor (VEGF) secretion in bone marrow stromal cells (BMSCs), without affecting their viability.	VX-745	67-73	interleukin 6	Homo sapiens	98-102
12393542-2	2003	In this study, we demonstrate that the specific p38 MAPK inhibitor VX-745 inhibits interleukin 6 (IL-6) and vascular endothelial growth factor (VEGF) secretion in bone marrow stromal cells (BMSCs), without affecting their viability.	VX-745	67-73	vascular endothelial growth factor A	Homo sapiens	108-142
12393542-2	2003	In this study, we demonstrate that the specific p38 MAPK inhibitor VX-745 inhibits interleukin 6 (IL-6) and vascular endothelial growth factor (VEGF) secretion in bone marrow stromal cells (BMSCs), without affecting their viability.	VX-745	67-73	vascular endothelial growth factor A	Homo sapiens	144-148
12393542-4	2003	Importantly, VX-745 inhibits both MM cell proliferation and IL-6 secretion in BMSCs triggered by adherence of MM cells to BMSCs, suggesting that it can inhibit paracrine MM cell growth in the BM milieu and overcome cell adhesion-related drug resistance.	VX-745	13-19	interleukin 6	Homo sapiens	60-64
11892915-6	2001	The targeting of p38 MAPK by VX-745 was associated with the suppression of the release of inflammatory mediators, including interleukin (IL)-1beta and tumor necrosis factor (TNF)alpha, known to be implicated in exacerbating the pathophysiology of RA [273648], [368149], [371548], [372054], [408713].	VX-745	29-35	tumor necrosis factor	Homo sapiens	174-183
12937622-9	2000	Development of p38 inhibitors has been slow, probably because of toxicological problems, which might explain why only two oral p38 inhibitors, SB-242235 and VX-745, have advanced into clinical development.	VX-745	157-163	mitogen activated protein kinase 14	Rattus norvegicus	15-18
12937622-9	2000	Development of p38 inhibitors has been slow, probably because of toxicological problems, which might explain why only two oral p38 inhibitors, SB-242235 and VX-745, have advanced into clinical development.	VX-745	157-163	mitogen activated protein kinase 14	Rattus norvegicus	127-130